Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
Quarterly results
DELCATH SYSTEMS, INC. (DCTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 4 Sylvester John Richard (Director) has filed a Form 4 on DELCATH SYSTEMS, INC.
Txns: Bought 10,550 shares @ $4.8, valued at $50.6k
08/22/2023 4 Rosalind Advisors, Inc. (Director) has filed a Form 4 on DELCATH SYSTEMS, INC.
Txns: Exercised (in-or-at-the-money) options to buy @ $1000, valued at $0
08/21/2023 4 MICHEL GERARD J (CEO) has filed a Form 4 on DELCATH SYSTEMS, INC.
Txns: Exercised (in-or-at-the-money) 31,110 options to buy @ $4.5, valued at $140k
08/16/2023 SC 13G Soleus Capital Master Fund, L.P. reports a 5.3% stake in Delcath Systems, Inc.
08/15/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, August 14, 2023/PRNewswire/ - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic me...",
"Corporate Presentation"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update"
08/04/2023 8-K Regulation FD Disclosure  Interactive Data
06/29/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/28/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/09/2023 3 Pennell Sandra (See Remarks) has filed a Form 3 on DELCATH SYSTEMS, INC.
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance NEW YORK, June 7, 2023 Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Ms. Pennell will also serve as an Executive Officer of the Company and its Principal Accounting Officer and Principal Financial Officer. Ms. Pennell joins the Company with over twenty-years of experience in a variety of financial oversight roles within the biotechnology industry and she will be responsible for managing all the Company's financial affairs, including preparing global financial statements for the guidance of management in accordance wit..."
05/12/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results"
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/31/2023 D Form D - Notice of Exempt Offering of Securities:
03/30/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/29/2023 8-K Quarterly results
03/27/2023 8-K Quarterly results
03/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Delcath Systems Announces up to $85 Million Financing"
03/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/24/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit NEW YORK, February 14, 2023/PRNewswire/ - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application resubmission to the US Food and Drug Administration for the HEPZATO ™ Kit seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma . The resubmission is in response to a September 12, 2013 Complete Response Letter from the FDA. The NDA resubmission contains comprehensive data and information to address all issues identified in the CRL. The FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for revi..."
01/23/2023 8-K Other Events  Interactive Data
01/23/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/20/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/10/2023 8-K Other Events  Interactive Data
01/10/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/03/2023 8-K Investor presentation
Docs: "Delcath Systems, Inc. corporate presentation",
"Delcath Systems, Inc. corporate presentation"
12/29/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy